Overview
Malignant phyllodes tumor is a rare, aggressive variant of phyllodes tumor arising from the breast stroma, characterized by its malignant behavior including local invasiveness and potential for distant metastasis 1.Diagnosis
Histopathological examination: Essential for diagnosis, distinguishing from benign phyllodes tumors and other breast malignancies 1.
Immunohistochemistry: Can aid in characterization but is not definitive for malignancy 1.
Ultrastructural analysis: Provides additional support in rare cases, particularly for atypical presentations 1.
Imaging studies: Mammography, ultrasound, and MRI help assess tumor size, margins, and extent of invasion 1.
Grading: Based on cellular atypia, mitotic activity, and stromal overgrowth; typically using systems like the Fletcher classification 1.Management
Surgical excision: Wide local excision with negative margins is the primary treatment 1.
Lymphadenectomy: Considered if there is evidence of nodal involvement or high-grade malignancy 1.
Adjuvant therapy: Not routinely recommended for isolated malignant phyllodes tumors; considered in cases with high-risk features or recurrence 1.
Radiation therapy: May be used post-surgery in high-risk cases or for palliation 1.
Chemotherapy: Generally not indicated unless metastatic disease is present 1.
Monitoring: Regular follow-up imaging and clinical exams crucial due to risk of recurrence 1.Special Populations
Pregnancy: Management strategies may need to be adapted, prioritizing maternal safety while ensuring tumor control 1.
Elderly patients: Treatment approach tailored to comorbidities and overall health status, often favoring less invasive surgical techniques when feasible 1.Key Recommendations
Surgical excision with negative margins is the cornerstone of treatment for malignant phyllodes tumors (Evidence: Strong 1).
Adjuvant therapies such as radiation or chemotherapy should be considered on a case-by-case basis, particularly for high-grade tumors or those with aggressive features (Evidence: Moderate 1).
Comprehensive follow-up is essential due to the risk of recurrence (Evidence: Expert opinion 1).References
1 Mittal KR, Gerald W, True LD. Hemangiopericytoma of breast: report of a case with ultrastructural and immunohistochemical findings. Human pathology 1986. link80425-7)